

# Introduction to the Design and Evaluation of Group Sequential Clinical Trials

Session 1 - Scientific Setting

Presented July 27, 2016

Daniel L. Gillen  
Department of Statistics  
University of California, Irvine

John M. Kittelson  
Department of Biostatistics & Informatics  
University of Colorado Denver

©2016 Daniel L. Gillen, PhD and John M. Kittelson, PhD

## Clinical Trials

Definition and Motivation  
Public Health Objective  
Statistical foundations  
Trial Monitoring: Motivation  
and Implications

SISCR - GSCT - 1 : 1

## Overview

### Module 9: Introduction to the Design and Evaluation of Group Sequential Clinical Trials

- Session 1:* Scientific setting
- Session 2:* Fixed-sample design
- Session 3:* Evaluation of group sequential clinical trial designs
- Session 4:* Bayesian evaluation of group sequential clinical trial designs

## Clinical Trials

Definition and Motivation  
Public Health Objective  
Statistical foundations  
Trial Monitoring: Motivation  
and Implications

SISCR - GSCT - 1 : 2

### A clinical trial is

- ▶ A planned experiment which involves patients that is designed to elucidate the most appropriate treatment of future patients. (Pocock, 1983)
- ▶ A planned experiment designed to assess the efficacy of a treatment in humans by comparing the outcomes in a group of patients treated with those observed in a comparable group of patients receiving a control treatment, where patients in both groups are enrolled, treated, and followed over the same time period. (Minert, 1986)

#### Clinical Trials

##### Definition and Motivation

Public Health Objective  
Statistical foundations  
Trial Monitoring: Motivation  
and Implications

### Types of questions that can be evaluated in clinical trials

- ▶ Therapeutic intervention studies:
  - ▶ Safety: Is risk of treatment-related toxicities suitably low?
  - ▶ Efficacy: Treatment benefits on disease processes?
  - ▶ Effectiveness: Does the treatment offer benefits when used as part of standard routine practice?
- ▶ Non-therapeutic intervention studies:
  - ▶ Mechanistic studies: Studies of drug mechanism of action.
  - ▶ Behaviorial interventions: Examples: Smoking cessation; diabetes prevention.
  - ▶ Prevention studies: Examples: Women's Health Initiative (HRT for prevention of cardiovascular disease); lung cancer screening trial.
  - ▶ Community intervention studies: Interventions on schools to promote healthy lifestyles.
- ▶ Our focus in this course is on medical intervention studies.

#### Clinical Trials

##### Definition and Motivation

Public Health Objective  
Statistical foundations  
Trial Monitoring: Motivation  
and Implications

### Clinical trials as experiments

- ▶ As scientific experiments clinical trials must:
  - ▶ Answer a scientifically meaningful questions.
    - Must discriminate between viable hypotheses
  - ▶ Provide results that inform (convince) medical practice.
    - Use valid materials and methods
    - Use valid measurement of the experimental outcome
    - Provide a valid quantification of uncertainty in the experiment.

#### Clinical Trials

##### Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation and Implications

### As experiments on humans clinical trials must:

- ▶ Be ethically justifiable for the individuals entering the trial:
  - As much as possible, minimize harm and maximize benefit for individuals in the trial.
  - Avoid giving individual participants harmful treatments.
  - Avoid giving individual participants inferior treatments.
- ▶ Maintain the ethical responsiveness to all likely future recipients of the therapy under evaluation:
  - Identify (and approve) new beneficial therapies.
  - Avoid approving ineffective or harmful treatments.
  - Avoid unnecessary delays in the evaluation process.

#### Clinical Trials

##### Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation and Implications

### Public Health Objective

- ▶ Evidence-based medicine requires:
  - ▶ Results in the sample reflect effects in standard practice.
    - Does the trial population reflect the target population?
    - Do diagnostic procedures reflect standard practice?
    - Does ancillary/rescue therapy reflect standard practice?
- ▶ (Reiterating) Our ultimate goal should be to:
  - ▶ Identify (and approve) new beneficial therapies.
  - ▶ Avoid approving ineffective or harmful treatments.

#### Clinical Trials

Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation and Implications

## The Public Health Objective

### Our objective is to have trials with high positive predictive value

- ▶ Positive predictive value (PPV):
  - ▶ *Diagnostic testing*: prevalence of diseased individuals among those with a positive diagnostic test.
  - ▶ *Clinical trials*: prevalence of truly beneficial therapies among those which are identified by a positive clinical trial.
- ▶ PPV is calculated using Bayes rule:

$$PPV = \frac{\beta\pi}{\beta\pi + \alpha(1 - \pi)}$$

where :

$$\beta = \textit{sensitivity}$$

$$1 - \alpha = \textit{specificity}$$

$$\pi = \textit{prevalence}$$

#### Clinical Trials

Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation and Implications

## The Public Health Objective

### Clinical trials as diagnostic tests

- ▶ The statistical hypothesis test is a diagnostic test for beneficial treatments.
  - ▶  $\alpha$ -level: probability of observing a positive (statistically significant) test in absence of a true treatment effect:
    - ▶ Level of significance is 1 - specificity.
    - ▶ Choosing  $\alpha = 0.05$  gives 95% specificity.
  - ▶ Statistical power ( $\beta$ ): Probability of observing a positive (statistically significant) test when there is a true treatment effect:
    - ▶ Power is sensitivity.
    - ▶ 80% sensitivity is a common (though not ideal) choice.
  - ▶ Prevalence ( $\pi_0$ ): the percentage of effective treatments among all tested treatments.
  - ▶ Positive predictive value: probability that a statistically significant trial indicates a truly effective treatment.

$$PPV = \frac{\beta\pi_0}{\beta\pi_0 + \alpha(1 - \pi_0)}$$

## The Public Health Objective: How does the design determine PPV?

### PPV is increased through good experimental practice

$$PPV = \frac{\beta\pi_0}{\beta\pi_0 + \alpha(1 - \pi_0)}$$

- \* Increase  $\pi_0$ :
  - Careful planning of preliminary studies
  - Avoid "novel" and "innovative" ideas
  - Careful specification of hypothesis-driven research
- \* Increase  $\beta$ :
  - Good practice (no missing data, low variation in outcome assessment, good adherence, etc.)
  - Increase sample size.
- \* Reduce  $\alpha$ :
  - Pre-specify outcomes
  - Pre-specify all analyses
  - Avoid multiple comparisons
  - Avoid surrogate outcomes.
  - Avoid subgroups

## The Public Health Objective: How does the design determine PPV?

### References: PPV as a function of $\pi_0$ , $\alpha$ , and $\beta$

\*\* *EfficiencyForTargetedTX.pdf* discusses effect of power (sensitivity) and  $\alpha$ -level (specificity) on the PPV of phase II/III clinical trials.

Scenario	Number of trials	$\pi_0$	Phase II trials		Phase III trials		Pos	Pos	PPV
			$\alpha_2$	$\beta_2$	$\alpha_3$	$\beta_3$			
1	1000	0.10	*	*	0.05	0.975	98	45	0.685
2	12500	0.10	0.05	0.15	0.05	0.800	150	28	0.842
3	11765	0.20	0.05	0.15	0.05	0.800	282	24	0.923
4	13245	0.01	0.05	0.15	0.05	0.800	16	33	0.327
5	9091	0.10	0.05	0.15	0.05	0.975	133	20	0.867
6	15385	0.10	0.05	0.15	0.05	0.500	115	35	0.769
7	6780	0.10	0.20	0.15	0.05	0.800	81	61	0.571
8	6780	0.10	0.20	0.15	0.10	0.800	81	122	0.400

\*\* *Evaluation of Strategies for the Phase II to Phase III Progression in Treatment Discovery:* (Sanchez, 2014) <http://rctdesign.org/TechReports/SanchezThesis201404.pdf>

#### Clinical Trials

Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation and Implications

## The Public Health Objective How do clinical trials determine PPV?

### Summary remarks

- ▶ A wide range of situations/therapies are studied in trials.
- ▶ Globally, clinical trials need to assure:
  - ▶ Scientific credibility
  - ▶ Ethical experiments
  - ▶ Efficient experiments:
    - ▶ Minimize time
    - ▶ Minimal number of extra subjects
    - ▶ Minimize cost
  - ▶ A high prevalence of truly beneficial therapies among all therapies used in routine care.

#### Clinical Trials

Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation and Implications

### Evidence-based practice

- ▶ As a scientific experiment, the results of a clinical trial are used to rule out (or rule in) hypotheses about treatment effects.
- ▶ The standards for rejecting (or accepting hypotheses) are based on statistical criteria.
- ▶ Clinical trial designs should be evaluated by the potential inference upon trial completion.

#### Clinical Trials

Definition and Motivation  
Public Health Objective

#### Statistical foundations

Trial Monitoring: Motivation  
and Implications

### Recall Empirical Objective:


Use observed trial result ( $\hat{\theta}$ ) to make inference about underlying population  $\theta$

#### Clinical Trials

Definition and Motivation  
Public Health Objective

#### Statistical foundations

Trial Monitoring: Motivation  
and Implications



### Four main inferential elements

1. Point estimate:  $\hat{\theta}$  is the “best” estimate of  $\theta$ .
2. Interval estimate: Values of  $\theta$  that are consistent with the trial results.
3. Expression of uncertainty ( $p$ -value): To what degree is a particular hypothesis (the “null” hypothesis) consistent with the observed trial results?
4. Decision: Based on the above measures, what decision should be reached about the use of a new therapy?

#### Clinical Trials

Definition and Motivation  
Public Health Objective

#### Statistical foundations

Trial Monitoring: Motivation  
and Implications

## Trial monitoring

### Why monitor a clinical trial?

- ▶ Monitoring for quality control; for example,
  - ▶ Patient accrual.
  - ▶ Data quality/completeness.
  - ▶ Unanticipated adverse events.
- ▶ Monitoring study endpoint(s); for example,
  - ▶ Treatment benefits.
  - ▶ Toxicity differences.
- ▶ Good quality control should be part of every study to ensure that the study achieves its goals.
- ▶ Monitoring study endpoints is not applicable in every study, and requires special statistical methods to avoid increased statistical errors.

#### Clinical Trials

Definition and Motivation  
Public Health Objective

#### Statistical foundations

Trial Monitoring: Motivation  
and Implications



### Reasons to monitor trial endpoints

- ▶ To maintain the validity of the informed consent for:
  - ▶ Subjects currently enrolled in the study.
  - ▶ New subjects entering the study.
- ▶ To ensure the ethics of randomization.
  - ▶ Randomization is only ethical under equipoise.
  - ▶ If there is not equipoise, then the trial should stop.
- ▶ To identify the best treatment as quickly as possible:
  - ▶ For the benefit of all patients (i.e., so that the best treatment becomes standard practice).
  - ▶ For the benefit of study participants (i.e., so that participants are not given inferior therapies for any longer than necessary).

#### Clinical Trials

Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation  
and Implications

### Monitoring trial endpoints

Monitoring endpoints must be done properly to avoid bias:

- ▶ Data driven analyses cause bias:
  - ▶ Analyzing study results because they look good leads to an overestimate of treatment benefits.
- ▶ Publication/presentation of 'preliminary results' can affect:
  - ▶ Ability to accrue subjects.
  - ▶ Type of subjects that are referred and accrued.
  - ▶ Treatment of patients not in the study.
- ▶ Failure to design for interim analyses can lead to hasty decisions subject to:
  - ▶ Inadequate consideration of trade-offs between competing endpoints (toxicity versus benefit).
  - ▶ External pressures from study investigators or sponsors.
  - ▶ Lack of objectivity by study monitors.

#### Clinical Trials

Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation  
and Implications

### Monitoring trial endpoints

Thus:

- ▶ Monitoring of study endpoints is often required for ethical reasons.
- ▶ Monitoring of study endpoints must carefully planned as part of study design to:
  - ▶ Avoid bias
  - ▶ Assure careful decisions
  - ▶ Maintain desired statistical properties

Clinical Trials

Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation  
and Implications

### How are trials monitored?

- ▶ “Data Safety and Monitoring Boards (DSMB)” are used to avoid biased decisions:
  - ▶ DSMB members are *independent* of the study investigators
  - ▶ The DSMB reviews unblinded data in the midst of a trial to:
    - Assure the trial is safe to continue.
    - Make decisions about early termination based on the statistical monitoring plan (“group-sequential clinical trial design”).
- ▶ DSMB composition:
  - ▶ Subject-matter specialists (2-4)
  - ▶ Biostatistician (1-2).

Clinical Trials

Definition and Motivation

Public Health Objective

Statistical foundations

Trial Monitoring: Motivation  
and Implications

## Elements of trial monitoring

### Trial monitoring plan

Trial monitoring plan is typically pre-specified in 2 documents:

- ▶ DSMB charter:
  - ▶ Defines scope of trial monitoring
  - ▶ Defines DSMB responsibilities
  - ▶ Defines sponsor responsibilities
  - ▶ Pre-specifies monitoring plans and decisions (reasons for stopping)
  
- ▶ Interim Statistical Analysis Plan (ISAP):
  - ▶ Defines monitoring endpoint(s)
  - ▶ Pre-specifies analysis timing, decision criteria, and rationale
  
  - ▶ Pre-specifies methods for implementation (changes to analysis timing)
  - ▶ Pre-specifies adjustments to statistical inference about treatment effects

## Monitoring the primary endpoint: Illustration of statistical implications

### Illustration setting (trial design):

Consider a clinical trial evaluating *superiority* of a new agent:

- ▶ Measure of treatment effect ( $\theta = \theta_1 - \theta_0$ ) defined based on fixed-sample design:
  - Primary endpoint
  - Probability model
  - Functional
  - Contrast
  - Statistical hypotheses
  - Statistical standards for decisions (i.e., frequentist or Bayes)
  
- ▶ Suppose large values of  $\theta$  denote superiority of the new agent.

## Monitoring the primary endpoint: Illustration of statistical implications

### Illustration setting (interim analysis plan):

- ▶ Suppose that the trial is planned with interim analyses after outcomes are measured on  $N_1 < N_2 < \dots < N_J$  participants.
- ▶ Let  $\hat{\theta}_j$  denote the estimated treatment effect at the  $j$ th analysis ( $j = 1, \dots, J$ ).
- ▶ Consider stopping criteria  $a_j < d_j$  with:

$$\hat{\theta}_j \geq d_j \Rightarrow \text{Decide new treatment is superior}$$


$$\hat{\theta}_j \leq a_j \Rightarrow \text{Decide new treatment is not superior}$$

$$a_j < \hat{\theta}_j < d_j \Rightarrow \text{Continue trial}$$

Set  $a_J = d_J$  so that the trial stops by the  $J$ th analysis.

## Illustration of statistical implications


Example: O'Brien-Fleming (OBF) 2-sided design



## Illustration of statistical implications

Example: OBF versus Pocock 1-sided designs

### One-sided superiority stopping boundaries




## Effect of stopping boundaries on the sampling density

[Simulated sample paths]


## Illustration of statistical implications

Example: O'Brien-Fleming (OBF) 2-sided design



## Illustration of statistical implications


Sampling density for OBF boundaries with  $\theta = 0$  and  $\theta = 3.92$  (corresponding Normal sampling density for comparison):



## Illustration of statistical implications


Example: OBF versus Pocock 1-sided designs

### One-sided superiority stopping boundaries



## Illustration of statistical implications

Sampling density for OBF and Pocock 1-sided designs.



## Illustration of statistical implications

Characteristics of the group sequential sampling density:

- ▶ Density is not shift invariant
- ▶ Jump discontinuities
- ▶ Requires numerical integration
- ▶ Sequential testing introduces bias:

$\theta$	$E(\hat{\theta})$	
	OFB	Pocock
0.00	-0.29	-0.48
1.96	1.95	1.82
3.92	4.21	4.38

- ▶ (Recursive form of the sequential sampling density is computationally useful.)
- ▶ Fully discussed in sections 3 and 6 of this course.